Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MTVA with free AI briefings, catalyst countdowns, and dilution alerts.

MTVA · MetaVia Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 9.5 months of cash at its recent burn rate (Jun 30, 2026 balance sheet), an at-the-market (ATM) program filed Jul 2, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$12.6M Cash on Hand
9.5mo Cash Runway
Follow MTVA by email Get an email when MTVA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MTVA, unsubscribe in one click. Privacy

📣 What MTVA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

MTVA holds $12.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $4M/quarter from operations, an estimated runway of 9.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MTVA files for a raise →

👥 Who Owns MTVA

Insiders 100% Institutions (18 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
DONG-A ST CO., LTD
10% owner · +3.82M options
Insider 9,995,679 148.24% 2025-05-08
Alyeska Investment Group, L.P. Institution (13G, 5%+) 508,585 7.54% 2026-03-31
Sarah Kaplan Browne
Chief Medical Officer
Insider 53,000 0.79% 2026-10-12
Hyung Heon Kim
CEO & President, Director
Insider 37,545 0.56% 2026-01-23
Marshall H Woodworth
Chief Financial Officer
Insider 30,734 0.46% 2026-01-23
D Gordon Strickland
Director
Insider 21,339 0.32% 2026-06-08
Andrew I Koven
Director
Insider 21,339 0.32% 2026-06-08
Michael Salsbury
Director
Insider 21,338 0.32% 2026-06-08
Jason L Groves
Director
Insider 21,338 0.32% 2026-06-08
Mark A Glickman
Director
Insider 20,629 0.31% 2026-06-08
James Patrick Tursi
Director
Insider 20,568 0.31% 2026-06-08

Share count 6,742,889 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MTVA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MTVA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.